AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34029160 — intervention group
Group type: EXPERIMENTAL
Intervention: Metsulfuron applied at 14 to 28 days after emergence (DAE)
Number of subjects: 4
Study 35220312 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis alone (1,000 mg/day)
Number of subjects: 55
Study 35220312 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis (1,000 mg/day) plus melatonin (20 mg/day)
Number of subjects: 55
Study 35220312 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin alone (20 mg/day)
Number of subjects: 55
Study 35220312 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 55
Study 32746654 — intervention group
Group type: EXPERIMENTAL
Intervention: NutrInform Battery
Number of subjects: 200
Study 32746654 — intervention group
Group type: COMPARATOR
Intervention: Nutri-Score
Number of subjects: 200
Study 33091589 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT‐I&N followed by CPT
Number of subjects: 222
Study 33091589 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT followed by CBT‐I&N
Number of subjects: 222
Study 33091589 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT followed by CPT
Number of subjects: 222
Study 36411426 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine (0.4 ml/kg)
Number of subjects: 74
Study 36411426 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine (0.8 ml/kg)
Number of subjects: 74
Study 36411426 — intervention group
Group type: COMPARATOR
Intervention: Both groups (0.25% and 0.125% bupivacaine)
Number of subjects: 74
Study 32769457 — intervention group
Group type: EXPERIMENTAL
Intervention: H&P 360 intervention with brief written instructions
Number of subjects: 159
Study 32769457 — intervention group
Group type: COMPARATOR
Intervention: Traditional H&P without additional instructions
Number of subjects: 159
Study 34126446 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-strength STP sludge
Number of subjects: 0
Study 34126446 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-strength STP sludge
Number of subjects: 0
Study 34126446 — intervention group
Group type: COMPARATOR
Intervention: Freshwater
Number of subjects: 0
Study 34126446 — intervention group
Group type: COMPARATOR
Intervention: Seawater
Number of subjects: 0
Study 34126446 — intervention group
Group type: COMPARATOR
Intervention: Half-strength seawater
Number of subjects: 0
Study 34328346 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse childhood experiences (ACEs)
Number of subjects: 42
Study 34328346 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (8 weeks)
Number of subjects: 42
Study 34328346 — intervention group
Group type: COMPARATOR
Intervention: SIRT1
Number of subjects: 42
Study 34328346 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow-mediated dilation (FMD)
Number of subjects: 42
Study 34887261 — intervention group
Group type: EXPERIMENTAL
Intervention: trilaciclib prior to GCb (days 1, 8)
Number of subjects: 102
Study 34887261 — intervention group
Group type: EXPERIMENTAL
Intervention: trilaciclib (days 1, 8) and trilaciclib prior to GCb (days 2, 9)
Number of subjects: 102
Study 34887261 — intervention group
Group type: EXPERIMENTAL
Intervention: trilaciclib prior to GCb (days 1, 8) and trilaciclib (days 1, 8)
Number of subjects: 102
Study 34887261 — intervention group
Group type: COMPARATOR
Intervention: GCb (days 1, 8)
Number of subjects: 102
Study 35113903 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated humidified O2
Number of subjects: 66
Study 35113903 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold humidified O2
Number of subjects: 66
Study 35113903 — intervention group
Group type: COMPARATOR
Intervention: Standard O2
Number of subjects: 66
Study 34786388 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg intravenous single dose one hour before TACE
Number of subjects: 100
Study 34786388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 32601879 — intervention group
Group type: EXPERIMENTAL
Intervention: Cam impingement morphology
Number of subjects: 51
Study 32601879 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegner Score, Harris Hip Score (HHS), and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Number of subjects: 51
Study 34870584 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT‐I)
Number of subjects: 56
Study 34870584 — intervention group
Group type: COMPARATOR
Intervention: Sleep Hygiene
Number of subjects: 56
Study 35080055 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) using Oculus GO with three-dimensional specific software content
Number of subjects: 96
Study 35080055 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham VR
Number of subjects: 96
Study 35080055 — intervention group
Group type: COMPARATOR
Intervention: Control group (no VR)
Number of subjects: 96
Study 35080055 — intervention group
Group type: EXPERIMENTAL
Intervention: VR
Number of subjects: 96
Study 33957506 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based programme (MBP)
Number of subjects: 280
Study 33957506 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based programme + Virtual Reality (MBP + VR)
Number of subjects: 280
Study 33957506 — intervention group
Group type: COMPARATOR
Intervention: Relaxation (active control)
Number of subjects: 280
Study 32871696 — intervention group
Group type: EXPERIMENTAL
Intervention: VRET
Number of subjects: 43
Study 32871696 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 43
Study 35627652 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart to Heart Card Game
Number of subjects: 66
Study 35627652 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 66
Study 33098211 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg orally once daily for 3 months (n = 12)
Number of subjects: 157
Study 33098211 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram treatment
Number of subjects: 157
Study 33098211 — intervention group
Group type: COMPARATOR
Intervention: Moderate to severe depressive symptoms (PHQ-9)
Number of subjects: 157
Study 33098211 — intervention group
Group type: COMPARATOR
Intervention: Clinical depression based on interview
Number of subjects: 157
Study 35240861 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alteplase
Number of subjects: 623
Study 35240861 — intervention group
Group type: COMPARATOR
Intervention: Endovascular treatment only (Control)
Number of subjects: 623
Study 32920808 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 4328
Study 32920808 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose edoxaban (HDER)
Number of subjects: 4328
Study 32920808 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose edoxaban (LDER)
Number of subjects: 4328
Study 35281950 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP+VSD treatment (group D)
Number of subjects: 84
Study 35281950 — intervention group
Group type: COMPARATOR
Intervention: Other algorithms
Number of subjects: 84
Study 32565319 — intervention group
Group type: EXPERIMENTAL
Intervention: External radiation boost (5 × 3 Gy) followed by standard pelvic chemoradiation (25 × 2 Gy with concurrent capecitabine)
Number of subjects: 128
Study 32565319 — intervention group
Group type: COMPARATOR
Intervention: Standard pelvic chemoradiation (25 × 2 Gy with concurrent capecitabine) without boost
Number of subjects: 128
Study 34244284 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical and oral antibiotic bowel preparation (MOABP) - 1g neomycin and 1g metronidazole two times on the day prior to surgery
Number of subjects: 604
Study 34244284 — intervention group
Group type: COMPARATOR
Intervention: Mechanical bowel preparation (MBP) - identical placebo
Number of subjects: 604
Study 34244284 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical and oral antibiotic bowel preparation (MOABP)
Number of subjects: 604
Study 34244284 — intervention group
Group type: COMPARATOR
Intervention: Mechanical bowel preparation (MBP)
Number of subjects: 604
Study 33159526 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (180-mg loading dose on day 1 followed by 90 mg twice daily for days 2-30) plus aspirin (300 to 325 mg on day 1 followed by 75 to 100 mg daily for days 2 to 30)
Number of subjects: 11016
Study 33159526 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus aspirin (300 to 325 mg on day 1 followed by 75 to 100 mg daily for days 2 to 30)
Number of subjects: 11016
Study 33159526 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (180-mg loading dose on day 1 followed by 90 mg twice daily for days 2-30) plus aspirin
Number of subjects: 11016
Study 33159526 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus aspirin
Number of subjects: 11016
Study 33159526 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 11016
Study 35510948 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (single 20 mg dose)
Number of subjects: 32
Study 35510948 — intervention group
Group type: COMPARATOR
Intervention: Both formulations
Number of subjects: 32
Study 34811370 — intervention group
Group type: EXPERIMENTAL
Intervention: H56:IC31 vaccination
Number of subjects: 51
Study 34811370 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib
Number of subjects: 51
Study 34811370 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib + H56:IC31
Number of subjects: 51
Study 34811370 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study 35654684 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin injection
Number of subjects: 0
Study 35654684 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 34145906 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional care interventions (care continuity and coordination, medication management, symptom recognition, self-management)
Number of subjects: 44
Study 32198304 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week mindfulness course followed by a 4-month maintenance phase
Number of subjects: 0
Study 32198304 — intervention group
Group type: COMPARATOR
Intervention: Text-based information about mindfulness (control group)
Number of subjects: 0
Study 35840157 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 50 mg once weekly
Number of subjects: 215
Study 35840157 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 215
Study 35840157 — intervention group
Group type: EXPERIMENTAL
Intervention: SASDAS
Number of subjects: 215
Study 35840157 — intervention group
Group type: EXPERIMENTAL
Intervention: ASDAS
Number of subjects: 215
Study 34529026 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly health education via WeChat
Number of subjects: 1525
Study 34529026 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1525
Study 35881649 — intervention group
Group type: EXPERIMENTAL
Intervention: HITSystem 2.1 eHealth intervention plus standard-of-care PMTCT services
Number of subjects: 12
Study 35881649 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care PMTCT services
Number of subjects: 12
Study 34473451 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-ups combined with a smartphone app (WeChat)
Number of subjects: 110
Study 34029149 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus Cisplatin
Number of subjects: 300
Study 34029149 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab plus Cisplatin plus Paclitaxel
Number of subjects: 300
Study 32919110 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 10 μg/day
Number of subjects: 594
Study 32919110 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 30 μg/day
Number of subjects: 594
Study 36128557 — intervention group
Group type: EXPERIMENTAL
Intervention: Trusilk ®
Number of subjects: 129
Study 36128557 — intervention group
Group type: EXPERIMENTAL
Intervention: Mersilk ®
Number of subjects: 129
Study 34041789 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinoid-containing product for 2 weeks (group A, n=36)
Number of subjects: 71
Study 34041789 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinoid-containing product for 8 weeks (group B, n=35)
Number of subjects: 71
Study 32057576 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA‐BN‐RSV high dose (1 × 10^8 TCID50)
Number of subjects: 63
Study 32057576 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA‐BN‐RSV low dose (1 × 10^7 TCID50)
Number of subjects: 63
Study 32057576 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA‐BN‐RSV (both doses)
Number of subjects: 63
Study 32057576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 32057576 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA‐BN‐RSV combined high dose groups
Number of subjects: 63
Study 35668121 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat bread enriched with α‐cyclodextrin (α‐CDB)
Number of subjects: 10
Study 35668121 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat bread enriched with hydroxytyrosol/α‐cyclodextrin complex ((HT + α‐CD)B)
Number of subjects: 10
Study 35668121 — intervention group
Group type: COMPARATOR
Intervention: White wheat bread (WB)
Number of subjects: 10
Study 35668121 — intervention group
Group type: COMPARATOR
Intervention: Glucose solution (reference food, GS)
Number of subjects: 10
Study 34620123 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral carbohydrate-rich (Ch-R) supplement taken 2 hours before elective caesarean delivery
Number of subjects: 88
Study 34620123 — intervention group
Group type: COMPARATOR
Intervention: Fasting
Number of subjects: 88
Study 35684118 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystine and theanine (CT)
Number of subjects: 32
Study 35684118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 32478806 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycled phototherapy
Number of subjects: 0
Study 32478806 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 34477469 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaine (BET) supplementation 2.4 g/day for 2 weeks
Number of subjects: 23
Study 33150572 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES + HPRO
Number of subjects: 25
Study 33150572 — intervention group
Group type: COMPARATOR
Intervention: SOC
Number of subjects: 25
Study 34600848 — intervention group
Group type: COMPARATOR
Intervention: Standard preoperative antibiotics
Number of subjects: 2803
Study 34600848 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedural factors (non-modifiable and modifiable)
Number of subjects: 2803
Study 34600848 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine skin preparation and antibiotic pocket wash
Number of subjects: 2803
Study 34236435 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc before breakfast (ZBB) - 25 mg zinc as zinc gluconate taken in the fasted state 30 min before breakfast
Number of subjects: 35
Study 34236435 — intervention group
Group type: COMPARATOR
Intervention: Zinc with breakfast (ZWB) - 25 mg zinc as zinc gluconate taken with breakfast
Number of subjects: 35
Study 32809261 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril‐valsartan
Number of subjects: 8399
Study 32809261 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 8399
Study 32809261 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium levels (hypokalaemia and hyperkalaemia)
Number of subjects: 8399
Study 32809261 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium abnormalities
Number of subjects: 8399
Study 35851028 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted surgery
Number of subjects: 70
Study 35851028 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic surgery
Number of subjects: 70
Study 33821322 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek BF (FBF; 3M ESPE)
Number of subjects: 138
Study 33821322 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetric EvoCeram BF (TBF; Ivoclar Vivadent)
Number of subjects: 138
Study 33821322 — intervention group
Group type: COMPARATOR
Intervention: Control Filtek Z250 (Z250; 3M ESPE)
Number of subjects: 138
Study 32758296 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleaching treatment with hydrogen peroxide 35% applied for 2 days (2×1 d)
Number of subjects: 120
Study 32758296 — intervention group
Group type: COMPARATOR
Intervention: No bleaching treatment (control group)
Number of subjects: 120
Study 35899811 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 vaccine (three doses)
Number of subjects: 0
Study 35899811 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vaccine)
Number of subjects: 0
Study 32491924 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable Resistance (WR) - additional load equivalent to 5% body mass
Number of subjects: 14
Study 35286196 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV vaccine administered to pregnant mothers
Number of subjects: 0
Study 35286196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36087116 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytate group (380 mg capsule of calcium‐magnesium InsP6 every 24 h for 3 months)
Number of subjects: 0
Study 36087116 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 0
Study 36087116 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytate group
Number of subjects: 0
Study 36087116 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 32302705 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT) using methylene blue as a photosensitizer activated by red and infrared diode laser
Number of subjects: 20
Study 32302705 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) using red and infrared diode laser
Number of subjects: 20
Study 33455471 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (10 weeks, 3 sessions/week)
Number of subjects: 18
Study 33455471 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 18
Study 34254834 — intervention group
Group type: EXPERIMENTAL
Intervention: Low oxalate diet (D)
Number of subjects: 164
Study 34254834 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with 25 mg vitamin B6 and 400 mg magnesium oxide (S)
Number of subjects: 164
Study 34254834 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of low oxalate diet and B6/magnesium supplementation (DS)
Number of subjects: 164
Study 32438990 — intervention group
Group type: EXPERIMENTAL
Intervention: Culprit-lesion-only PCI strategy
Number of subjects: 624
Study 32438990 — intervention group
Group type: COMPARATOR
Intervention: Immediate multivessel PCI strategy
Number of subjects: 624
Study 32613224 — intervention group
Group type: EXPERIMENTAL
Intervention: HF-rTMS over the left DLPFC
Number of subjects: 25
Study 32613224 — intervention group
Group type: EXPERIMENTAL
Intervention: HF-rTMS over the right DLPFC
Number of subjects: 25
Study 32613224 — intervention group
Group type: COMPARATOR
Intervention: Sham HF-rTMS
Number of subjects: 25
Study 32613224 — intervention group
Group type: EXPERIMENTAL
Intervention: HF-rTMS over the left and right DLPFC
Number of subjects: 25
Study 33323209 — intervention group
Group type: EXPERIMENTAL
Intervention: American Heart Association website prompt group
Number of subjects: 1075
Study 33323209 — intervention group
Group type: EXPERIMENTAL
Intervention: Hourly stand prompt group
Number of subjects: 1075
Study 33323209 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster-specific prompts group
Number of subjects: 1075
Study 33323209 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 daily step prompt group
Number of subjects: 1075
Study 35156734 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateralized subthalamic stimulation (unilateral 50% amplitude reduction) for ≥21 days
Number of subjects: 22
Study 35156734 — intervention group
Group type: COMPARATOR
Intervention: Control group (bilateral subthalamic stimulation)
Number of subjects: 22
Study 34408569 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with house dust mite (HDM) for 24 months
Number of subjects: 96
Study 34408569 — intervention group
Group type: COMPARATOR
Intervention: Control treatment for 24 months
Number of subjects: 96
Study 35317973 — intervention group
Group type: EXPERIMENTAL
Intervention: ProBio intervention (specifics not provided)
Number of subjects: 0
Study 34189249 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 mg/day intepirdine
Number of subjects: 269
Study 34189249 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 mg/day intepirdine
Number of subjects: 269
Study 34189249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269
Study 33087220 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy (LLLT)
Number of subjects: 36
Study 33087220 — intervention group
Group type: COMPARATOR
Intervention: Formocresol (FC)
Number of subjects: 36
Study 33319444 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of controlled‐release morphine
Number of subjects: 68
Study 33319444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 34353073 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL)
Number of subjects: 132
Study 34353073 — intervention group
Group type: COMPARATOR
Intervention: Palpebral gland massage combined with a hot compress
Number of subjects: 132
Study 33149896 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% NaOCl irrigating the canals without PUI activation
Number of subjects: 40
Study 33149896 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% NaOCl with PUI
Number of subjects: 40
Study 33149896 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% NaOCl gel irrigating the canals without PUI
Number of subjects: 40
Study 33149896 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% NaOCl gel with PUI
Number of subjects: 40
Study 35649241 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.4 g psyllium fiber supplementation twice a day for 1 week before surgery
Number of subjects: 84
Study 35649241 — intervention group
Group type: COMPARATOR
Intervention: No fiber supplementation before surgery
Number of subjects: 84
Study 34245038 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Body Project (6 meetings over 6 weeks)
Number of subjects: 35